Barts Liver Centre, Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.
J Viral Hepat. 2019 Jan;26(1):4-15. doi: 10.1111/jvh.13040. Epub 2018 Dec 11.
Despite the availability of a preventative vaccine, chronic hepatitis B (CHB) remains a global healthcare challenge with the risk of disease progression due to cirrhosis and hepatocellular carcinoma. Although current treatment strategies, interferon and nucleos(t)ide analogues have contributed to reducing morbidity and mortality related to CHB, these therapies are limited in providing functional cure. The treatment paradigm in CHB is rapidly evolving with a number of new agents in the developmental pipeline. However, until novel agents with functional cure capability are available in the clinical setting, there is a pressing need to optimize currently licensed therapies. Here, we discuss current agents used alone and/or in combination strategies along with the impact of these therapies on viral and immune responses. Novel treatment strategies are outlined, and the potential role of current therapies in the employment of pipeline agents is discussed.
尽管有预防性疫苗可用，但慢性乙型肝炎 (CHB) 仍然是一个全球性的医疗保健挑战，存在因肝硬化和肝细胞癌而导致疾病进展的风险。尽管目前的治疗策略，包括干扰素和核苷（酸）类似物，有助于降低与 CHB 相关的发病率和死亡率，但这些疗法在提供功能性治愈方面存在局限性。CHB 的治疗模式正在迅速发展，许多新的药物正在研发中。然而，在具有功能性治愈能力的新型药物在临床应用之前，迫切需要优化目前已获得许可的治疗方法。在这里，我们讨论了单独使用和/或联合治疗策略的现有药物，以及这些疗法对病毒和免疫反应的影响。概述了新的治疗策略，并讨论了现有疗法在使用管道药物方面的潜在作用。
